On January 8, 2024, Akebia Therapeutics, Inc. announced the appointment of Richard C. Malabre as Chief Accounting Officer and principal accounting officer, effective January 8, 2024. Mr. Malabre will report directly to the Company?s Senior Vice President, Chief Financial Officer, Treasurer and principal financial officer, Ellen Snow. Mr. Malabre, age 63, served as the Chief Financial Officer and Treasurer of Ultivue, Inc, a diagnostic company, from March 2021 to September 2023.

From September 2023 to December 2023, Mr. Malabre also served as a Senior Advisor to Ultivue, Inc. and as an independent financial consultant. Prior to joining Ultivue, Inc., Mr. Malabre served as the Vice President and Corporate Controller of Oxford Immunotec USA, Inc., formerly Oxford Immunotec, Inc., a medical diagnostic company, from 2012 to March 2021. Prior to joining Oxford Immunotec, USA, Inc., Mr. Malabre served in various positions at Salient Surgical Technologies, Inc., Medtronic, Inc., NueroMetrix, Inc., Charles River Associates, Enterasys Networks, Inc. and Teradyne, Inc. Mr. Malabre began his financial career at Coopers & Lybrand and is a United States Navy Supply Corps veteran.

He is a C.P.A. and received a M.S. in Management from MIT and a B.A. in economics from Trinity College, Hartford, CT.